New Clinical Trial Shows Lenacapavir Reduces HIV Infection Risk by 96%
A recent Phase III clinical trial has demonstrated that a biannual injection of lenacapavir lowers the risk of HIV infection by 96%. In the study, 99% of participants who received lenacapavir did not contract HIV. While approved for use in…